Abacavir

Abacavir is a nucleoside reverse transcriptase inhibitor used in combination with other anti-retroviral medications indicated for the treatment of HIV. Abacavir is generally well-tolerated by patients, however, in 5–8 % of individuals undergoing treatment, a hypersensitivity reaction occurs (Martin et al. 2012). Symptoms of hypersensitivity include fever, rash, fatigue, cough, gastrointestinal symptoms, and dyspnea (shortness of breath). A genetic variant in HLA-B, HLA-B57:01, is associated with this hypersensitivity reaction in about 6 % of patients (Martin et al. 2012). This association has been reviewed by Martin et al. (2012). Not only was this association observed in retrospective analyses of clinical trials, there was also a prospective, double-blind, randomized clinical trial of a genetic test to reduce adverse events through screening for HLA-B57:01 before treatment (PREDICT-1) (Mallal et al. 2008). Based on the results of this trial and other supporting evidence, th.

Abacavir is a nucleoside reverse transcriptase inhibitor used in combination with other anti-retroviral medications indicated for the treatment of HIV. Abacavir is generally well-tolerated by patients, however, in 5–8 % of individuals undergoing treatment, a hypersensitivity reaction occurs (Martin et al. 2012). Symptoms of hypersensitivity include fever, rash, fatigue, cough, gastrointestinal symptoms, and dyspnea (shortness of breath). A genetic variant in HLA-B, HLA-B57:01, is associated with this hypersensitivity reaction in about 6 % of patients (Martin et al. 2012). This association has been reviewed by Martin et al. (2012). Not only was this association observed in retrospective analyses of clinical trials, there was also a prospective, double-blind, randomized clinical trial of a genetic test to reduce adverse events through screening for HLA-B57:01 before treatment (PREDICT-1) (Mallal et al. 2008). Based on the results of this trial and other supporting evidence, th.

Abacavir is generally well-tolerated by patients, however, in 5–8 % of individuals undergoing treatment, a hypersensitivity reaction occurs.

<p>Abacavir is generally well-tolerated by patients, however, in 5–8 % of individuals undergoing treatment, a hypersensitivity reaction occurs.</p> Signup and view all the answers

<p>Symptoms of hypersensitivity include fever, rash, fatigue, cough, gastrointestinal symptoms, and dyspnea (shortness of breath).</p> Signup and view all the answers

<p>Symptoms of hypersensitivity include fever, rash, fatigue, cough, gastrointestinal symptoms, and dyspnea (shortness of breath).</p> Signup and view all the answers

<p>A genetic variant in HLA-B, HLA-B*57:01, is associated with this hypersensitivity reaction in about 6 % of patients (Martin et al. 2012). This association has been reviewed by Martin et al. (2012).</p> Signup and view all the answers

<p>A genetic variant in HLA-B, HLA-B*57:01, is associated with this hypersensitivity reaction in about 6 % of patients (Martin et al. 2012). This association has been reviewed by Martin et al. (2012).</p> Signup and view all the answers

<p>Not only was this association observed in retrospective analyses of clinical trials, there was also a prospective, double-blind, randomized clinical trial of a genetic test to reduce adverse events through screening for HLA-B*57:01 before treatment (PREDICT-1) (Mallal et al. 2008). Based on the results of this trial and other supporting evidence, th.</p> Signup and view all the answers

<p>Not only was this association observed in retrospective analyses of clinical trials, there was also a prospective, double-blind, randomized clinical trial of a genetic test to reduce adverse events through screening for HLA-B*57:01 before treatment (PREDICT-1) (Mallal et al. 2008). Based on the results of this trial and other supporting evidence, th.</p> Signup and view all the answers

<p>5-8%</p> Signup and view all the answers

<p>Fever, rash, and fatigue</p> Signup and view all the answers

<p>HLA-B*57:01</p> Signup and view all the answers

<p>Through a retrospective analysis of clinical trials</p> Signup and view all the answers

<p>To reduce adverse events through screening for HLA-B*57:01 before treatment</p> Signup and view all the answers